<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: Provocation tests of <z:e sem="disease" ids="C0010073" disease_type="Disease or Syndrome" abbrv="">coronary artery spasm</z:e> are useful for the diagnosis of vasospastic <z:mp ids='MP_0006112'>angina</z:mp> (VSA) </plain></SENT>
<SENT sid="1" pm="."><plain>However, these tests are thought to have a potential risk of arrhythmic complications, including <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> (VT), <z:hpo ids='HP_0001663'>ventricular fibrillation</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e>), and brady-<z:hpo ids='HP_0011675'>arrhythmias</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>We aimed to elucidate the safety and the clinical implications of the spasm provocation tests in the nationwide multicentre registry study by the Japanese <z:e sem="disease" ids="C0010073" disease_type="Disease or Syndrome" abbrv="">Coronary Spasm</z:e> Association </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS AND RESULTS: A total of 1244 VSA patients (M/F, 938/306; median 66 years) who underwent the spasm provocation tests were enrolled from 47 institutes </plain></SENT>
<SENT sid="4" pm="."><plain>The primary endpoint was defined as major adverse cardiac events (MACEs) </plain></SENT>
<SENT sid="5" pm="."><plain>The provocation tests were performed with either <z:chebi fb="9" ids="15355">acetylcholine</z:chebi> (<z:chebi fb="0" ids="15355">ACh</z:chebi>, 57%) or ergonovine (40%) </plain></SENT>
<SENT sid="6" pm="."><plain>During the provocation tests, VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> and brady-<z:hpo ids='HP_0011675'>arrhythmias</z:hpo> developed at a rate of 3.2 and 2.7%, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>Overall incidence of arrhythmic complications was 6.8%, a comparable incidence of those during spontaneous <z:mp ids='MP_0006112'>angina</z:mp> attack (7.0%) </plain></SENT>
<SENT sid="8" pm="."><plain>Multivariable logistic regression analysis demonstrated that diffuse right <z:e sem="disease" ids="C0010073" disease_type="Disease or Syndrome" abbrv="">coronary artery spasm</z:e> (P &lt; 0.01) and the use of <z:chebi fb="0" ids="15355">ACh</z:chebi> (P &lt; 0.05) had a significant correlation with provocation-related VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>During the median follow-up of 32 months, 69 patients (5.5%) reached the primary endpoint </plain></SENT>
<SENT sid="10" pm="."><plain>The multivariable Cox proportional hazard model revealed that mixed (focal plus diffuse) type multivessel spasm had an important association with MACEs (adjusted hazard ratio, 2.84; 95% confidence interval, 1.34-6.03; P &lt; 0.01), whereas provocation-related <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> did not </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSION: The spasm provocation tests have an acceptable level of safety and the evaluation of spasm type may provide useful information for the risk prediction of VSA patients </plain></SENT>
</text></document>